Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Intravenous Iron Drugs Market Size Changed, over the years?

In recent years, the market for intravenous iron medications has seen a substantial increase in size. Its growth is projected to continue, with an increase from $3.44 billion in 2024 to $3.84 billion in 2025, representing a compound annual growth rate (CAGR) of 11.6%. Factors contributing to the growth during the historic period include the growing prevalence of iron deficiency anemia, an increase in chronic illnesses, heightened healthcare expenditure, an aging global demographic, and a rise in the occurrence of related diseases.

How Much Will the Intravenous Iron Drugs Market Be Worth in 2029?

The market size for intravenous iron medications is predicted to experience significant expansion in the coming years. It is estimated to reach $5.86 billion by 2029, with a compound annual growth rate (CAGR) of 11.2%. The projected growth in this period can be attributed to several factors such as government initiatives, enhanced research and development within the IV iron drugs sector, a rise in demand for intravenous iron treatments, an increase in research and development programs, and progress in administration and formulation techniques. Key trends anticipated during this forecast period include the development of advanced intravenous iron treatments, breakthroughs in drug development, a movement towards more convenient IV iron therapies, strategic collaborations, partnerships and acquisitions, and innovative new drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Which is the Largest Company in the Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

What Are the Main Market Drivers in the Intravenous Iron Drugs Industry?

The intravenous iron drugs market is projected to expand due to the rising prevalence of chronic kidney disease (CKD). CKD is characterized by the progressive loss of kidney function, resulting in the organ’s inability to properly eliminate waste and excess fluid from the blood. The surge in CKD cases can be mainly attributed to the increased incidence of diabetes and hypertension, both of which lead to kidney damage over time. Intravenous iron medications aid CKD patients by restoring iron levels, rectifying anemia, and raising hemoglobin levels, thereby improving oxygen transportation and minimizing the need for erythropoiesis-stimulating agents. For example, the Australian Institute of Health and Welfare, a governmental agency based in Australia, reported a 4.2% increase in CKD mortality in 2021 and a 6.2% rise in 2022. In the year 2022, CKD accounted for approximately 22,000 fatalities in Australia, representing 11% of all reported deaths. Therefore, the escalating cases of CKD is fueling the growth of the intravenous iron drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

How Is the Intravenous Iron Drugs Market Segments Structured?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Strategic Trends Are Transforming the Intravenous Iron Drugs Market?

Leading firms in the intravenous iron drugs market are prioritizing the generation of novel therapies such as intravenous (IV) iron replacement therapy, with the intention of enhancing effectiveness, safety, and patient results. This therapy, which delivers iron directly into the bloodstream via an IV drip, is used to manage iron deficiency and anemia, predominantly in patients who struggle to adequately absorb or tolerate oral iron supplements. Daiichi Sankyo Company Limited, an innovative pharmaceutical and healthcare solutions company based in Japan, revealed in June 2023, that the U.S. Food and Drug Administration (FDA) had given the green light for Injectafer (ferric carboxymaltose injection) to be used in treating adults with heart failure classified as New York Heart Association class II/III, for the purpose of improving exercise capacity. Injectafer is noted for being a widely embraced intravenous iron therapy due to its ability to promptly restore iron levels in patients who cannot absorb or tolerate oral iron supplements effectively.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Offer the Highest Growth in the Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430

This Report Delivers Insight On:

1. How big is the intravenous iron drugs market, and how is it changing globally?

2. Who are the major companies in the intravenous iron drugs market, and how are they performing?

3. What are the key opportunities and risks in the intravenous iron drugs market right now?

4. Which products or customer segments are growing the most in the intravenous iron drugs market?

5. What factors are helping or slowing down the growth of the intravenous iron drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model